# US 10,308,723 B2 · Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,723 B2
- Document ID: US10308723B2
- Status: Granted
- Kind: B2
- Application number: 15/482,260
- Filed: 2017-04-07
- Published: 2017-10-26
- Granted: 2019-06-04
- Earliest claimed: 2012-10-01
- Assignees: Ucb Biopharma Sprl
- Applicants: Ucb Biopharma Sprl
- Inventors: Ralph Adams; Andrew George Popplewell; Stephen Edward Rapecki
- Web page: https://patentgrep.com/patent/US10308723B2

## CPC

- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/04: for throat disorders
- A61P 11/06: Antiasthmatics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/244: {Interleukins [IL]}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

## Claims

### Claim 1

A method of treating inflammation associated with an increased level of IL-17A and/or IL-17F in a subject in need thereof comprising administering to the subject an antibody which binds human IL-17A and human IL-17F, wherein the variable domain of the antibody heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3, and wherein the variable domain of the antibody light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, or an antigen binding fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody is a whole antibody.

### Claim 3 (depends on 2)

The method of claim 2, wherein the heavy chain variable region of the antibody comprises the amino acid sequence set forth in SEQ ID NO: 9.

### Claim 4 (depends on 2)

The method of claim 2, wherein the light chain variable region of the antibody comprises the amino acid sequence set forth in SEQ ID NO: 7.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antigen binding fragment is a Fab, Fab′, F(ab′)2, or scFv.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody or antigen binding fragment thereof is conjugated to one or more effector molecule(s).

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is suffering from arthritis, rheumatoid arthritis, asthma, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, inflammatory bowel disease, Ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme arthritis, meningoencephalitis, multiple sclerosis and Guillain-Barr syndrome, pancreatitis, graft-versus-host disease, transplant rejection, myocardial infarction, atherosclerosis or intravascular coagulation.

### Claim 8

A method of treating inflammation associated with an increased level of IL-17A and/or IL-17F in a subject in need thereof comprising administering to the subject an antibody which binds human IL-17A and human IL-17F, wherein the antibody binds to the same epitope on human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer as a neutralising antibody which binds human IL-17A and human IL-17F, and comprises a heavy chain variable region having the amino acid sequence given in SEQ ID NO:9 and a light chain variable region having the amino acid sequence given in SEQ ID NO:7.

### Claim 9 (depends on 8)

The method of claim 8, wherein the subject is suffering from arthritis, rheumatoid arthritis, asthma, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, inflammatory bowel disease, Ulcerative colitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme arthritis, meningoencephalitis, multiple sclerosis and Guillain-Barr syndrome, pancreatitis, graft-versus-host disease, transplant rejection, myocardial infarction or intravascular coagulation.